Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease focal segmental glomerulosclerosis (FSGS). The company's already ...

Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...

The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $50.45 / share. This is an ...

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five ...

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...

In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Merck & Company, with a price target of $140.00. Claim 55% Off TipRanks. Unlock hedge fund-l ...

Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.

Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...

By John Vandermosten, CFA NASDAQ: LGND | NASDAQ: XOMA In an April 27th press release, Ligand Pharmaceuticals, Inc. (NASDAQ: ...